Characterization of primary isolate-like variants of simian-human immunodeficiency virus - Wikidata - awgldk - TriplyDB

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

http://www.wikidata.org/entity/Q33825229

about

Recombinant gas vesicles from Halobacterium sp. displaying SIV peptides demonstrate biotechnology potential as a pathogen peptide delivery vehicle.Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge.Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.Eliciting neutralizing antibodies with gp120 outer domain constructs based on M-group consensus sequence.Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells.A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERS Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones.Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine.Detailed characterization of antibody responses against HIV-1 group M consensus gp120 in rabbits.HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells.Comparison of the genotypic and phenotypic properties of HIV-1 standard subtype B and subtype B/B' env molecular clones derived from infections in China.

P2860

Q33317659-C45EBEDC-78A4-46B1-B300-BFDF2E567BBC Q33737656-55D12543-582C-427E-90A8-3FE508BF6BE6 Q33835295-0AD0E1D7-CD0F-475C-8799-9C5092DB36B2 Q33839402-E9040E2D-F58D-4F93-B46B-AF21519A2A71 Q33842286-E546E384-09E5-448B-B795-2AE32662A39D Q33847697-D16B8511-8129-414D-9BC0-2B4F0349B904 Q33850605-3A555B09-9579-4064-B13D-BBC9B57E360D Q33851802-08600A90-41DC-4D13-9135-93D017DB2FC1 Q33852768-ED98F726-7570-4DCE-8C4E-5AE9061DCF99 Q33941033-894B3771-21D5-487D-91F7-C056CBAB21B6 Q34016706-F9E0281C-528D-4DE6-9F41-31F97DD5CA66 Q34301874-953AA684-60E2-4D7A-9F45-33DD62D2AE7D Q34332009-499DDE1A-30AC-4E53-94A1-A7AC3FED31AE Q34344205-136396D7-4357-4447-B941-CD10C57C6A91 Q34546037-95B1E367-7AD3-4F2D-895F-AA25EBCBC658 Q35077039-5419C368-94BD-4874-9E3C-6986E2992C3B Q35123128-6EB18A1D-77F3-4537-A444-262E837E3E7B Q35155451-A1870AC6-636C-431C-A4FF-E1D3044DC828 Q35690771-58F68DEA-D7C5-4233-80FF-C49DC22FEF1A Q35925858-943F1C1B-B6C7-4BCA-9755-E0428863AB65 Q35973601-C66971F4-0EC8-4E15-AF0E-5597272E1531 Q36138144-DEB1CEE4-6F9E-4759-B791-AAF015A127C8 Q36141610-4F9D42DB-4306-4ABB-831A-0036B04F3596 Q36525047-E4F21351-D5D6-423C-9875-86B85F12A482 Q37009569-1C57AB86-8312-4038-B801-FAE9A63CA120 Q37094160-7AF96D47-7BF0-4561-8AAC-380D7E57EF44 Q37181874-066C036A-2BE5-4353-9C03-B7F9E234A846 Q37547702-19AC9BD9-2A2D-45BC-BEF1-B1F578494D76 Q37682968-D2439D6A-7FAD-46C5-804D-904F35D3B94F Q37683291-B6573AB5-4FB7-4748-9BC5-116DCCAC4BB5 Q37742938-602771DD-321B-49F0-A3AD-D62A33E8C642 Q39682485-420A4D09-6A7B-4E07-A010-B3F652F62BF1 Q39699309-6C42D984-9872-4E8A-B7B9-42C95593F4B5 Q42148035-B3CB4AE4-BC4A-4734-A85C-C91477FC1DE3 Q47399269-2F7E5ADE-2C4D-457B-8F97-8BEAD61DB75D Q54209545-82EEC53D-1447-400F-B21E-93D68D590C6A

P2860

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

http://www.wikidata.org/entity/Q33825229

description

1999 nî lūn-bûn

@nan

1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@ast

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@en

type

label

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@ast

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@en

prefLabel

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@ast

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@en

P1433

Q33825229-F1DE42D6-5FE6-465F-8A73-8560B7EF5A51

P1476

Q33825229-69F15CB4-0B33-4156-9FA7-3983B258AE4B

P2093

Q33825229-022C9D26-1B3D-453E-B10F-E3F0285BB9AB

Q33825229-3182A176-672B-44FD-8B26-2C2576DC6DE9

Q33825229-443D094C-14D0-4332-826E-B7DF7D39E9C0

Q33825229-620FCA67-C832-47A5-AB6B-F61274405AC7

Q33825229-6C1D1AE3-29BC-4900-80AC-98C38992DEA3

Q33825229-6CAE8B53-A08F-4589-8753-68AB4E73FD20

Q33825229-788FE8CC-CD2C-4E6B-8BFA-20B2376A5547

Q33825229-898B5D59-DBD8-497F-B0C9-E2CA1B03423D

Q33825229-90F18494-1A82-47EA-942F-B4FD3AB50FEB

Q33825229-9C9FB3AC-80DC-4AAB-9F67-7B330DECD00A

P2860

Q33825229-0AFCF094-1C33-4D5A-A56A-1C987031F061

Q33825229-0B2816D3-3D9F-4FE3-B6B4-18ED6ADE5A7A

Q33825229-0B37480D-62F9-4FB1-93C0-D891FCBA6C4C

Q33825229-0D4360E6-AD0D-4237-9589-B38A8CCE3B95

Q33825229-0EB77352-3FEA-456F-AD97-3FE3A97D1B99

Q33825229-0EEE16EB-B742-4F92-A82A-0B3933DDB42E

Q33825229-1BF090DC-E435-441E-BE0F-679E48390177

Q33825229-1DE45FA7-5F01-4F0D-BD00-9B0A8ED8A4EA

Q33825229-2089B21B-CD8C-4104-8F8B-671E68FEC606

Q33825229-21C1D409-30D9-4BF5-A83A-919009C03021

P304

Q33825229-C1CB358E-4D9F-4049-8175-63D044679E73

P31

Q33825229-7A51F335-1C00-487F-9277-1352962988A0

P433

Q33825229-F416E941-C031-4ABB-8BDA-7F0421456108

P478

Q33825229-CB4DBBC7-89F4-4050-A9C8-531B07575F8A

P50

Q33825229-34A46A3E-B45A-4271-B083-FF423AF70D82

P577

Q33825229-E48AEDB5-5971-47BE-BF7F-2601F00B40E1

P698

Q33825229-D9BF31F0-83C0-4D01-9E2C-FD841C897E55

P932

Q33825229-052B61CB-BCE1-4963-84A4-4059DD777823

P1433

Journal of Virology

P1476

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

@en

P2093

B Moss

http://www.w3.org/2001/XMLSchema#string

C D Pauza

http://www.w3.org/2001/XMLSchema#string

D C Montefiori

http://www.w3.org/2001/XMLSchema#string

D R Burton

http://www.w3.org/2001/XMLSchema#string

J G Sodroski

http://www.w3.org/2001/XMLSchema#string

J M Crawford

http://www.w3.org/2001/XMLSchema#string

J T Zhou

http://www.w3.org/2001/XMLSchema#string

K A Reimann

http://www.w3.org/2001/XMLSchema#string

K H Manson

http://www.w3.org/2001/XMLSchema#string

M Bilska

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

A new classification for HIV-1

HIV entry and its inhibition

The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide

Persistent infection of macaques with simian-human immunodeficiency viruses

Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

P304

10199-10207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10559336

http://www.w3.org/2001/XMLSchema#string

P932

113073

http://www.w3.org/2001/XMLSchema#string